Finance

Beta
Lists
SMMT:BMV
Summit Therapeutics Inc
MX$290.12
0.00%
(0.00) 1D
May 26, 10:29:53 AM GMT-6  ·   MXN
All symbols
SymbolPriceChange% Change
Generating top insights for SMMT...
Mkt. cap
11.70B
Avg. vol.
79.00
Volume
0.00
52-wk high
MX$430.00
52-wk low
MX$281.00
No. of employees
265
Mkt. cap
11.70B
Avg. vol.
79.00
Volume
0.00
52-wk high
MX$430.00
52-wk low
MX$281.00
No. of employees
265
News stories
From sources across the web
About Summit Therapeutics Inc
CEORobert Duggan | Maky Zanganeh
Employees265
Founded2003
Headquarters-
SectorBiotechnology
Websitesmmttx.com
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
208.02M
131.10M
147.29M
132.62M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
360.42M
103.12M
77.63M
62.59M
Operating expense
568.44M
234.21M
224.92M
195.21M
Total operating expenses
568.44M
234.21M
224.92M
195.21M
Operating income
-568.44M
-234.21M
-224.92M
-195.21M
Other non operating income
-53.00K
-
-
-
EBT including unusual items
-565.71M
-231.79M
-219.17M
-189.42M
EBT excluding unusual items
-565.71M
-231.79M
-219.17M
-189.42M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-565.71M
-231.79M
-219.17M
-189.42M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
2.98M
2.78M
5.88M
5.85M
Interest expense
-
-
-
-
Net interest expenses
2.98M
2.78M
5.88M
5.85M
Depreciation and amortization charges
-
-
-
-
EBITDA
-568.40M
-234.17M
-224.88M
-195.17M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer